Cargando…

Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308859/ https://www.ncbi.nlm.nih.gov/pubmed/25889583 http://dx.doi.org/10.1186/s13075-015-0529-1

Ejemplares similares

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
por: Verbrugge, Sue Ellen, et al.
Publicado: (2013)

High susceptibility of c-KIT(+)CD34(+) precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model
por: van de Ven, Rieneke, et al.
Publicado: (2011)

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
por: Oerlemans, Ruud, et al.
Publicado: (2018)

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR
por: Verbrugge, Sue Ellen, et al.
Publicado: (2015)

Positioning of proteasome inhibitors in therapy of solid malignancies
por: Roeten, Margot S. F., et al.
Publicado: (2017)

Modulating the Ubiquitin–Proteasome System: A Therapeutic Strategy for Autoimmune Diseases
por: Yadav, Dhananjay, et al.
Publicado: (2022)

(Immuno)proteasomes as therapeutic target in acute leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2017)

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
por: de Gruijl, Tanja D., et al.
Publicado: (2008)

Are we ready for therapeutic drug monitoring of biologic therapeutics?
por: Krieckaert, Charlotte LM, et al.
Publicado: (2011)

Proteasome inhibitors as complementary or alternative antiviral therapeutics
por: Prosch, Susanna, et al.
Publicado: (2006)

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis
por: Hsu, Sheng-Min, et al.
Publicado: (2015)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

Therapeutic targeting of cancer cell cycle using proteasome inhibitors
por: Rastogi, Namrata, et al.
Publicado: (2012)

Site-Specific Proteasome Inhibitors
por: Kisselev, Alexei F.
Publicado: (2021)

Proteasome inhibitors in glioblastoma
por: Huang, Wen-Juan, et al.
Publicado: (2017)

Proteasome inhibitors in glioblastoma
por: Huang, Wen-Juan, et al.
Publicado: (2017)

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
por: LaPlante, Gabriel, et al.
Publicado: (2021)

Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease
por: Barabas, Arpad Z, et al.
Publicado: (2007)

Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
por: Sherman, David J., et al.
Publicado: (2020)

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis
por: Geusens, Piet, et al.
Publicado: (2008)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
por: Yu, Zhen, et al.
Publicado: (2022)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics
por: Mir, Reyaz Hassan, et al.
Publicado: (2023)

Recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2
por: Ibtisam, Ibtisam, et al.
Publicado: (2023)

Prophylactic and Therapeutic Effect of Kynurenine for Experimental Autoimmune Encephalomyelitis (EAE) Disease
por: Sundaram, Gayathri, et al.
Publicado: (2022)

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors
por: Vigneron, Nathalie, et al.
Publicado: (2015)

Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
por: Keino, Hiroshi, et al.
Publicado: (2008)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
por: Banham-Hall, Edward, et al.
Publicado: (2012)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors
por: Hui, Kwai Fung, et al.
Publicado: (2017)

The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes
por: Mondanelli, Giada, et al.
Publicado: (2017)

Thrombotic microangiopathy associated with proteasome inhibitors
por: Lodhi, Ahad, et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Proteasome inhibitors against amelanotic melanoma
por: Sidor-Kaczmarek, Justyna, et al.
Publicado: (2017)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Nostocyclopeptides as New Inhibitors of 20S Proteasome
por: Fidor, Anna, et al.
Publicado: (2021)

An unstructured proteasome inhibitor comes into focus
por: Nemec, Antonia A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6aok67kooiu4fbuol4ojiskm6n